3T Biosciences

3T Biosciences, founded in 2017 and based in South San Francisco, focuses on developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases. The company originated from work conducted in Dr. K. Christopher Garcia’s lab at Stanford University and launched with $40 million in Series A financing. 3T Biosciences has entered into a second partnership with Boehringer Ingelheim to advance cancer immunotherapies. The company utilizes a proprietary platform technology, 3T-TRACE (T Cell Receptor Antigen and Cross-Reactivity Engine), which combines high-diversity target libraries with active machine learning to identify novel targets and T cell receptors (TCRs). This platform aids in the development of therapies that are specific, safer, and more effective for broad patient populations. 3T Biosciences focuses on identifying shared targets and therapeutically active TCRs and T cell receptor mimetics (TCRm). The company employs machine learning algorithms for high-throughput and comprehensive profiling of TCR specificity and explores opportunities across multiple therapeutic areas, including autoimmune diseases and viral infections. Their therapeutic modalities include TCRm bispecifics, peptide vaccines, and novel TCR cell therapies. By leveraging data science, bioinformatics, and engineering, 3T Biosciences accelerates target discovery and therapeutic development. The company is located at 201 Haskins Way, 5th Floor, South San Francisco, CA 94080.